Quantum Cyber N.V. (QUCY): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Quantum Cyber N.V. (QUCY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of William Caragol, Chief Financial Officer On November 20, 2026, William Caragol notified Quantum Cyber N.V.,

Event · Exec change
Person
David Caplon
Title
Chief Financial Officer
Action
appointed
Effective
November 20, 2026
Predecessor
William Caragol
Also in this documentExec change · resigned

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 20, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$QUCY
Neutral
medium confidence
Mentioned
$QUCY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QUCYNeutralMed
01

Why it matters

The disclosure provides concrete compensation and vesting/severance provisions for the incoming CFO, which can influence near-term sentiment around governance, reporting continuity, and potential change-in-control-related costs.

02

Market read

This is a primary executive-change filing with specific financial terms, useful for traders assessing governance and potential dilution/cost implications.

03

What to watch

Investors may underweight the equity and severance mechanics, including accelerated vesting tied to termination without cause or within 12 months of a change in control, which can affect future dilution and cash costs.

Relevance 6/10Novelty 6/10Timing: effective immediately on Nov. 20, 2026, with compensation and vesting details disclosed today

Background

The company filed an SEC Form 8-K under Item 5.02 covering CFO resignation, CFO appointment, and the new CFO’s employment and equity promotion terms.

Company-level read

Ticker impact

$QUCYNeutralMedium confidence
Context

Quantum Cyber N.V. disclosed CFO William Caragol’s resignation and the appointment of David Caplon as CFO effective Nov. 20, 2026, with defined compensation and severance.

Expected impact

Likely modest volatility or neutral-to-slight negative reaction as investors price execution and transition risk, partially offset by continuity via an internal controller hire.

Evidence & confidence

The filing is a primary SEC disclosure of an executive change with specific salary, bonus, equity grant size, and severance triggers, but it does not provide performance metrics or business outlook.

Market effects

Signals governance and finance-function continuity for a small-cap public issuer, which can affect perceived reporting and internal-control risk in the broader microcap tech/quantum-adjacent space.

Limited direct regional spillover; the event is company-specific within a Netherlands-domiciled issuer reporting to US investors.

Low, as there is no cross-border deal, regulatory action, or macro linkage described.

Counterpoint

Because Caplon was already the company’s Controller since June 2026, the transition may be viewed as low-risk operational continuity rather than disruption.

Key entities

  • Quantum Cyber N.V.

    Netherlands-domiciled company filing the 8-K, reporting CFO transition and executive compensation details.

  • William Caragol

    Resigning CFO, with a consulting agreement at $15,000 per month and continued vesting of prior equity awards.

  • David Caplon

    Appointed CFO effective Nov. 20, 2026, previously Controller since June 2026, with base salary, bonus target, equity grant parameters, and severance/acceleration terms.

Related articles

$QUCYMed

Quantum Cyber Reports First Revenue of ~$1.0 Million and Announces $8.0 Million Funding Commitment From Chief Executive Officer David Lazar Third Quarter…

Quantum Cyber N.V. (QUCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum Cyber Reports First Revenue of ~$1.0 Million and Announces $8.0 Million Funding Commitment From Chief Executive Officer David Lazar Third Quarter 2026 Form 10-Q Highlights: ● Four customers each accounting for 10% or more of quarterly revenue, with no single

$QUCYMed

Quantum Cyber N.V. (QUCY) Appoints Maj. Gen. Rosende to Board

Quantum Cyber N.V. (QUCY) added Maj. Gen. (Ret.) Alberto C. Rosende to its board to oversee its Bridgeport, CT facility and supply chain for autonomous drones. The move supports the company's focus on domestic, vertically integrated manufacturing to meet U.S. demand, which could become a revenue catalyst if milestones are met.

$QUCYLow

Quantum Cyber N.V. (QUCY): Completion of Acquisition or Disposition of Assets

Quantum Cyber N.V. (QUCY) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001874252 00-0000000 0001874252 2026-07-15 2026-07-15 0001874252 dei:FormerAddressMember 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sect

$ORCLMed

Oracle says OpenAI infrastructure deal is fully funded after final capital raise

Oracle announced its infrastructure deal with OpenAI is fully funded after a $20B capital raise. Shares rose 3.3% in after-hours trading. The company plans to expand data-center capacity, including a 4.5GW project in the US. Oracle confirmed financing is in place, with additional vendor discussions as options. The Abilene campus, where OpenAI’s GPT-6 Astra was trained, is nearly complete.

$SXTPHighAI 9/10

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc.…

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Na